PD184352 (CI-1040)

Catalog No.S1020

PD184352 (CI-1040) Chemical Structure

Molecular Weight(MW): 478.67

PD184352 (CI-1040) is an ATP non-competitive MEK1/2 inhibitor with IC50 of 17 nM in cell-based assays, 100-fold more selective for MEK1/2 than MEK5. Phase 2.

Size Price Stock Quantity  
In DMSO USD 140 In stock
USD 70 In stock
USD 120 In stock
USD 270 In stock
USD 670 In stock
USD 770 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 43 Publications

12 Customer Reviews

  • The inhibitor PD173074 (A) or PD184352 (B) was administered to one uterine horn of Hand2d/d mice on day 3 of pregnancy (n = 5). The other horn served as vehicle-treated control. Uterine horns were collected on the morning of day 4, and sections were subjected to IHC to detect p-FRS2, p-ERK1/2, and Ki-67. (C) IHC of pERa and Muc-1 in uterine sections of Hand2d/d mice treated with PD173074 or PD184352.

    Science 2011 331, 912-916. PD184352 (CI-1040) purchased from Selleck.

     

    Melanoma cell viability and in vivo growth by cyclindependent kinase 2/4 inhibition. Western blot analysis for c-Jun, phosphorylated-ERK1/2 (Thr202/Tyr204) (p-ERK1/2), and total ERK1/2 protein levels was done for human melanoma cell lines treated with the BRAFV600E inhibitor GDC-0879 (1 μM), or MEK inhibitors CI-1040 (1 μM), U0126 (1 μM), and PD98059 (10 μM) for 18 hours.

    J Natl Cancer Inst 2012 104(21), 1673-9. PD184352 (CI-1040) purchased from Selleck.

  •  

    Melanoma cell viability and in vivo growth by cyclindependent kinase 2/4 inhibition. In vivo growth of LOXIMVI xenografts in athymic nude Foxn1nu mice is shown. Tumors were allowed to grow to a maximum volume of 250 mm3, and the mice were subsequently treated daily at the indicated dose levels with CDK2/4 inhibitors by intraperitoneal injection in combination with a BRAFV600E- or MEK-inhibitor. CDK2/4 inhibitor (CVT-313/indolocarbazole CDK4-I) treatment sensitizes tumors to GDC-0879 and CI1040.

    J Natl Cancer Inst 2012 104(21), 1673-9. PD184352 (CI-1040) purchased from Selleck.

    LY294002 (10 μM for 12 h)- and PD184352 (10 μM for 12 h)-treated Her2-transfected DU145 and PC3 cells, respectively, showed reciprocal feedback inhibition between the PI3K/AKT and MEK/ERK path ways

    Proc Natl Acad Sci U S A 2011 108, 16392-7. PD184352 (CI-1040) purchased from Selleck.

  • The effect of CI-1040 on cell viability of molecular apocrine lines. MTT assay to measure cell viability in MDA-MB-453 cell line after treatment with CI-1040 (CI) at 2 to 25 μM concentrations. MTT assay to measure cell viability in HCC-1954 cell line after treatment with CI-1040 at 2 to 25 μM concentrations.

    Breast Cancer Res 2011 13, R36. PD184352 (CI-1040) purchased from Selleck.

    Combination indices (CI) for flutamide (FLU) and CI-1040 combination therapy in MDA-MB-453-R line using MTT assay. Therapies were carried out with flutamide at 5 and 10 μM with each concentration of CI-1040 at 5 and 10 μM (CI-5 and CL-10). The concentrations of fluatmide and CI-1040 monotherapies with an effect similar to that of each combination therapy are depicted. Error bars: ±2SEM. Western blot analysis was used to measure the phosphorylated and total ERK levels in MDA-MB-453-R line following combination therapies with CI-1040 (5 μM)/flutamide (5 μM) and CI-1040 (5 μM)/flutamide (10 μM). RR values were measured relative to the untreated MDA-MB-453-R line.

    Breast Cancer Res 2011 13, R36. PD184352 (CI-1040) purchased from Selleck.

  • Western blot analysis to measure the phosphorylated and total ERK levels in MDA-MB-453 and HCC-1954 cell lines after treatment with CI-1040 (CI) at 10-μM concentration.

     

     

    Neoplasia 2011 13, 154–166. PD184352 (CI-1040) purchased from Selleck.

    Relative expression of AR using RT-PCR in MDA-MB-453 and HCC-1954 cell lines after treatment with CI-1040 (MEK Inh) at 10-μMconcentration for 24 hours. Expression is relative to that of vehicle-treated cells (CTL). *P < .01 is for CI-1040 versus control. Error bars,±2 SEMs.

     

     

    Neoplasia 2011 13, 154–166. PD184352 (CI-1040) purchased from Selleck.

  • Synergistic effect of AR and mitogen-activated protein kinase kinase inhibitors on cell viability. (A) MTT assay to measure cell viability in MDA-MB-453 cell line after monotherapies and combination treatments with flutamide (FLU) and CI-1040 (CI) at 5 and 10 μΜ concentrations. CTL: control. Error bars: ±2 SEM. (B) Combination indices (CI) for flutamide and CI-1040 combination therapy in MDA-MB-453 cell line using MTT assay. Cell viability was measured after combination therapies with flutamide at 5 and 10 μM with each concentration of CI-1040 at 5 and 10 μM. The concentrations of FLU and CI-1040 monotherapies with an effect similar to that of each combination therapy are depicted. Error bars: ±2 SEM. (C) Combination indices for flutamide and CI-1040 combination therapy in HCC-1954 cell line using MTT assay. Cell viability was measured after combination therapies with flutamide at 20 and 40 μM with each concentration of CI-1040 at 5 and 10 μM. (D) Combination indices for flutamide and CI-1040 combination therapy in HCC-202 cell line using MTT assay at concentrations described in Figure 2C.

     

     

    Neoplasia 2011 13, 154–166. PD184352 (CI-1040) purchased from Selleck.

    After starved in serum-free medium for 24h, Breast cancer cells incubated with the indicated concentrations of CI-1040 for 3h,followed by 15-minute stimulation of 100ng/ml EGF

     

     

    2010 Dr. Zhang of Tianjin Medical University. PD184352 (CI-1040) purchased from Selleck.

  • After starved in serum-free medium for 24h, Breast cancer cells incubated with the indicated concentrations of CI-1040 for 3h,followed by 15-minute stimulation of 100ng/ml EGF

     

    2010 Dr. Zhang of Tianjin Medical University. PD184352 (CI-1040) purchased from Selleck.

    The bar chart represents the relative numbers of third-round colonies of primary hematopoietic cells transduced with MLL-AF9 with treatment of compound PD184352 (CI-1040, 10 μM, a MEK inhibitor) and SB216763 (10 μM, GSK-3 inhibitor). The synergic effect between compounds CI-1040 and SB-216763 has been observed.

     

     

    2010 Dr. Shuo Dong of Baylor College of Medicine. PD184352 (CI-1040) purchased from Selleck.

Purity & Quality Control

Choose Selective MEK Inhibitors

Biological Activity

Description PD184352 (CI-1040) is an ATP non-competitive MEK1/2 inhibitor with IC50 of 17 nM in cell-based assays, 100-fold more selective for MEK1/2 than MEK5. Phase 2.
Features First MEK inhibitor to begin clinical development.
Targets
MEK1 [1]
(Cell-free assay)
MEK2 [1]
(Cell-free assay)
17 nM 17 nM
In vitro

CI-1040 treatment produces a reduction of pMAPK levels in multiple tumor cells including Colon 26, BX-PC3 pancreatic, A431 cervical, HT-29 colon, ZR-25-1 breast and SKOV-3 ovarian carcinomas. CI-1040 treatment doesn't inhibit the phosphorylation of Jun kinase, p38 kinase or Akt, indicating CI-1040 specifically targets MEK. Inhibition of MAPK activation by CI-1040 prevents cell cycle progression and induces a G1 block. [1] The IC50 for inhibition of MEK1 by CI-1040 is 0.3 μM, 15-fold higher than the concentration required to inhibit the EGF-induced activation of ERK2 in Swiss 3T3 cells. These results indicate CI-1040 exerts its effects on cells by suppressing the activation of MKK1, and not by blocking its activity. 2 nM PD184352 inhibits the activation of MKK1 in Swiss 3T3 cells by 50%, while over 100-fold concentration of CI-1040 inhibits MEK1 in vitro. PD184352 also inhibits the Raf-catalysed phosphorylation of MEK1 without any effect on the Raf-catalysed phosphorylation of myelin basic protein. [2] CI-1040 inhibits 86% of papillary thyroid carcinoma (PTC) cell growth with the RET/PTC1 rearrangement at 10μM compared with cells treated with DMSO only. CI-1040 shows potent inhibition to PTC cells (BRAF mutation) with GI50 of 52 nM, but low activity to RET/PTC1 rearrangement type with GI50 of 1.1 μM. [3] A recent research indicates CI-1040 increases the apoptotic effect of BMS-214662 in a CML blast crisis cell line, K562, and in primary chronic phase CD34+ CML cells. [4]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
H9 NVXoV|ZzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEXITHZKSzVyPUCuNFIzPzZizszN MUPTRW5ITVJ?
CHP-212 Mn7PS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYCyTVk4UUN3ME2wMlAzQDh3IN88US=> MYjTRW5ITVJ?
EoL-1-cell MmK4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkfBTWM2OD1yLkC0NVUzKM7:TR?= NV\WPFM3W0GQR1XS
DU-4475 NInkb5pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkLjTWM2OD1yLkC3OVk6KM7:TR?= M1fXXnNCVkeHUh?=
MMAC-SF NFnPe4pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn7wTWM2OD1yLkGwPVc1KM7:TR?= M{PmU3NCVkeHUh?=
AGS MmfVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWXh[FU4UUN3ME2wMlEyPzF|IN88US=> NXTXdnJ[W0GQR1XS
M14 NG\HXoNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1vyXmlEPTB;MD6xOVQ3QCEQvF2= MnXOV2FPT0WU
CP50-MEL-B MmDKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MofhTWM2OD1yLkG3NlU1KM7:TR?= Mn76V2FPT0WU
C32 MkLaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlvuTWM2OD1yLkG5NFczKM7:TR?= M1jlWXNCVkeHUh?=
KMOE-2 NEL2eYRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXrJR|UxRTBwMUm3PVUh|ryP MYLTRW5ITVJ?
A101D M4qyRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NU\wdm5tUUN3ME2wMlIyPCEQvF2= M1fYNnNCVkeHUh?=
KM12 MnXhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWHJR|UxRTBwMkSwOVch|ryP NYXKUJZtW0GQR1XS
HSC-4 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF6zNZNKSzVyPUCuNlQ{QTVizszN NFHCRXVUSU6JRWK=
NOMO-1 MofKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF7FfWdKSzVyPUCuNlU4PDJizszN MVrTRW5ITVJ?
MZ7-mel MoL3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2S5fWlEPTB;MD6yOlM1KM7:TR?= MnrGV2FPT0WU
ACN NH;UZXlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUDJR|UxRTBwMk[3N|ch|ryP NWGxS5BEW0GQR1XS
MEL-HO MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mk\FTWM2OD1yLkK3OlUzKM7:TR?= NUXzb5N2W0GQR1XS
BHT-101 NG\BU|RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUDkXopvUUN3ME2wMlI5PjB4IN88US=> NE\qOJRUSU6JRWK=
SK-MEL-28 NUXWSWZWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2nEbmlEPTB;MD6zNFQxQSEQvF2= M1S3SnNCVkeHUh?=
KG-1 NF7lTlhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUHJR|UxRTBwM{C2Olgh|ryP NXXQU5hRW0GQR1XS
COLO-679 MkO4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUKxXIlQUUN3ME2wMlMzPzJizszN NX\3b2NTW0GQR1XS
SK-MEL-24 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4jQfWlEPTB;MD6zNlgyOyEQvF2= M1zD[XNCVkeHUh?=
G-361 NHKyeGRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4fvcWlEPTB;MD6zOlc6PSEQvF2= MlLiV2FPT0WU
KY821 M1TK[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlnDTWM2OD1yLkO3PVEh|ryP M2nPSXNCVkeHUh?=
KASUMI-1 Mn7FS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M124UmlEPTB;MD6zPVkh|ryP NE\iSW9USU6JRWK=
HL-60 MoP0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEnxd3ZKSzVyPUCuOFEyODdizszN NUTWXpVOW0GQR1XS
K5 MoTxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFz0SWhKSzVyPUCuOFMyOTdizszN NXezR2Q5W0GQR1XS
KU812 NUTvUWcxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX7aZ5huUUN3ME2wMlQ2Ojl7IN88US=> M1f0WnNCVkeHUh?=
SH-4 NVH3clg3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{DDXGlEPTB;MD60OlI2PiEQvF2= MnPjV2FPT0WU
HTC-C3 M4\VVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkjSTWM2OD1yLkS2OVMyKM7:TR?= MUXTRW5ITVJ?
CP66-MEL NGPh[pNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mm\1TWM2OD1yLkS4PFA6KM7:TR?= MlL3V2FPT0WU
WM-115 MkO1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NETldHlKSzVyPUCuOFkzPTdizszN M2fL[3NCVkeHUh?=
A2780 NHXvTY1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYDJR|UxRTBwNEm4NlMh|ryP M2Sye3NCVkeHUh?=
P12-ICHIKAWA M{nYb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV3JR|UxRTBwNkGyNlEh|ryP NV7RU4ZnW0GQR1XS
HMV-II Mn75S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M33jeWlEPTB;MD62OFQ3PSEQvF2= NHGwd5hUSU6JRWK=
HT-144 M2n6R2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYLvV3h1UUN3ME2wMlY1PjV5IN88US=> MnfsV2FPT0WU
LB2518-MEL MmS3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlXDTWM2OD1yLkexOlMzKM7:TR?= MkLPV2FPT0WU
NCI-SNU-1 Mn3vS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFjyVWNKSzVyPUCuO|U1OzNizszN Ml\0V2FPT0WU
C2BBe1 MkfsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYjvUpJqUUN3ME2wMlgyODJ|IN88US=> MV\TRW5ITVJ?
PSN1 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFPEbGxKSzVyPUCuPVYyQTZizszN NITrdYZUSU6JRWK=
UACC-257 MkjVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH;aeplKSzVyPUCuPVY1PzNizszN MW\TRW5ITVJ?
RVH-421 NGnTVVFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWH6OZNmUUN3ME2wMlk4OThizszN M3jVV3NCVkeHUh?=
GP5d NXLuWZpCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{PZc2lEPTB;MD65PFMxQCEQvF2= MWTTRW5ITVJ?
TYK-nu MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVPJR|UxRTFwMEOxO|Ih|ryP Mnz6V2FPT0WU
SK-N-AS MlvCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEPIO29KSzVyPUGuNFc6PDdizszN Mo[yV2FPT0WU
SW620 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2\icmlEPTB;MT6xN|U{PCEQvF2= MVTTRW5ITVJ?
HuP-T4 NFOz[ZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFf2eGNKSzVyPUGuNVg{PTlizszN NIjWTm1USU6JRWK=
A549 NYfVcWkyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVXvTmJkUUN3ME2xMlE6PTd4IN88US=> NHf3TXBUSU6JRWK=
Mewo M4XGV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1nmVmlEPTB;MT6yNFI4PiEQvF2= M1jId3NCVkeHUh?=
ONS-76 NGq4cpRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4jlNmlEPTB;MT6yNlA1QSEQvF2= MVPTRW5ITVJ?
SK-MEL-1 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGTxNG1KSzVyPUGuNlM1OTlizszN NIe5XldUSU6JRWK=
RCM-1 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV34dlVZUUN3ME2xMlI1ODR5IN88US=> NEnt[lFUSU6JRWK=
H-EMC-SS MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUnsVlU6UUN3ME2xMlI6PjB6IN88US=> M4rGRXNCVkeHUh?=
NCI-H2291 NVvneJVXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFrhdGtKSzVyPUGuN|I2OzZizszN MUnTRW5ITVJ?
SW1463 NULw[XZqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVzkRWR1UUN3ME2xMlM{PzJzIN88US=> NXqzNW9mW0GQR1XS
LS-411N M4Tqfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX;JR|UxRTFwNEC1NVch|ryP NHn2RXlUSU6JRWK=
BV-173 MnTtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIL0NYpKSzVyPUGuOFQxOTVizszN MnG5V2FPT0WU
LS-513 NYixXYFrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M36xV2lEPTB;MT60OVE6OiEQvF2= M2rP[XNCVkeHUh?=
LoVo NWDIVWN5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3nmT2lEPTB;MT60OlM6QSEQvF2= MV3TRW5ITVJ?
HO-1-N-1 NH\OWZBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkPGTWM2OD1zLkWxOlM1KM7:TR?= MUHTRW5ITVJ?
ML-2 NUfuXWs1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUjCWpoxUUN3ME2xMlUzQDZ6IN88US=> NE\wUYVUSU6JRWK=
NCI-H1437 NInXRllIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHXLZnpKSzVyPUGuOVUzPzVizszN M2LWWXNCVkeHUh?=
SW1116 M3fiTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYXJR|UxRTFwNU[zPVgh|ryP MmHlV2FPT0WU
A4-Fuk NYrMVJN2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml:wTWM2OD1zLkW3NFQ2KM7:TR?= NYK0SlU{W0GQR1XS
HD-MY-Z MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH3HfpFKSzVyPUGuOVc{PzZizszN NUXuepJmW0GQR1XS
SK-MEL-2 M2G4XWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVjJR|UxRTFwNUe0OVkh|ryP NUTkSXNVW0GQR1XS
RT-112 NUG5SGdRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnH1TWM2OD1zLkW4PVUzKM7:TR?= NYXUTm9wW0GQR1XS
COLO-829 M4HkO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYnJR|UxRTFwNkKyN|Ih|ryP NF3GOYJUSU6JRWK=
OVCAR-5 NUDaXFFyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWjYRphOUUN3ME2xMlc4Pjh5IN88US=> MnLpV2FPT0WU
NB69 M1Oydmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFLr[IlKSzVyPUGuO|g1PjlizszN M{f2NXNCVkeHUh?=
NCI-H292 NIjLblJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoPQTWM2OD1zLki2Olk6KM7:TR?= NXPz[lhxW0GQR1XS
LOXIMVI M{DsPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX3JR|UxRTFwOEm0Nlch|ryP M1rEbXNCVkeHUh?=
BPH-1 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUDrSFI4UUN3ME2xMlg6PTlzIN88US=> NWLFXXRXW0GQR1XS
A375 Mom1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXTtPXZ5UUN3ME2xMlg6PzF2IN88US=> NXzTTZgyW0GQR1XS
LCLC-97TM1 M{PwbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVPJR|UxRTFwOUKyOVYh|ryP NGXS[VNUSU6JRWK=
RXF393 M4TSXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIrIOoVKSzVyPUGuPVc5QDdizszN MWPTRW5ITVJ?
HCC70 MoXSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2XKbWlEPTB;Mj6wNlQzPiEQvF2= NFr6OG1USU6JRWK=
EM-2 NYPwfVZVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGfGSFdKSzVyPUKuNFcyQThizszN NV;aNms2W0GQR1XS
MZ2-MEL MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF;1NpVKSzVyPUKuNVEyOjdizszN MV;TRW5ITVJ?
HN NHj3RpFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoT5TWM2OD1{LkG2Nlc5KM7:TR?= MWTTRW5ITVJ?
A2058 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUHqU453UUN3ME2yMlE6Ojd7IN88US=> M3;ifXNCVkeHUh?=
NB7 NVjtU4RGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn\hTWM2OD1{LkO0NFg3KM7:TR?= MYnTRW5ITVJ?
DOK NVH0U4tmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NW[3UG5VUUN3ME2yMlM2Pzd|IN88US=> NVLmb4NtW0GQR1XS
CAL-27 NVz1d5VPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnGyTWM2OD1{LkO5NlM3KM7:TR?= MVzTRW5ITVJ?
BB65-RCC NWfUWoxbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4nqfWlEPTB;Mj60NFY4PCEQvF2= MXfTRW5ITVJ?
RD NHXCcFFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVLq[HJ[UUN3ME2yMlQ1PzJ|IN88US=> MXLTRW5ITVJ?
KNS-62 NF\wbYlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3fVNGlEPTB;Mj61NVE3PCEQvF2= NHPkbmxUSU6JRWK=
EW-13 Mm\nS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mne0TWM2OD1{LkW2N|M6KM7:TR?= NUDUZ2M2W0GQR1XS
DB NGrDdI9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFrGVY9KSzVyPUKuOVg4QDhizszN M3vjVnNCVkeHUh?=
HCC2218 NG\0eIpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXzJR|UxRTJwNkS3O|gh|ryP MYPTRW5ITVJ?
L-363 NWHN[Hh3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYTJR|UxRTJwN{SzO{DPxE1? MoPOV2FPT0WU
CHL-1 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{G5RmlEPTB;Mj64NFc5PSEQvF2= M2nUTHNCVkeHUh?=
BFTC-905 NWK4WFBkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFP3XmFKSzVyPUKuPFI2OyEQvF2= NIH5[plUSU6JRWK=
HCE-T M1:2PGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFvwVYhKSzVyPUKuPFMzPjRizszN MYfTRW5ITVJ?
COLO-792 NF;UfWVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmnBTWM2OD1{Lki0NFI4KM7:TR?= M3zqTHNCVkeHUh?=
LB2241-RCC NXLlfYFYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn;KTWM2OD1{Lki1PFk{KM7:TR?= MYLTRW5ITVJ?
CAL-39 NEnnV25Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWr0b45QUUN3ME2yMlg6QTl7IN88US=> MV;TRW5ITVJ?
T-24 NYK0SmNMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlrLTWM2OD1{LkmxNVEzKM7:TR?= NF\XNmpUSU6JRWK=
NCI-H727 NFHMeWFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlTCTWM2OD1{LkmxO|k3KM7:TR?= NYjzZZA2W0GQR1XS
Ca9-22 MkLPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnXJTWM2OD1{Lkm3NlU2KM7:TR?= NYLrZ49mW0GQR1XS
MIA-PaCa-2 M4Lodmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2\WdmlEPTB;Mz6wNFc5OSEQvF2= NGnFcIpUSU6JRWK=
HT-1080 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn\6TWM2OD1|LkCxPVk4KM7:TR?= MlTlV2FPT0WU
D-423MG MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2m4dWlEPTB;Mz6wO|c2OyEQvF2= MY\TRW5ITVJ?
LAMA-84 MnXjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYLmNJBwUUN3ME2zMlE{PThizszN MVPTRW5ITVJ?
SW780 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUnJR|UxRTNwMUSyNlkh|ryP MkTBV2FPT0WU
KU-19-19 NX[5fIxjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGfmTFRKSzVyPUOuNVcxOzRizszN M13Bb3NCVkeHUh?=
COLO-741 M17rSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mo\STWM2OD1|LkG4Olc{KM7:TR?= MVnTRW5ITVJ?
HSC-3 NUDwfWh[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4Sxe2lEPTB;Mz6yN|E2OSEQvF2= NGLvS3pUSU6JRWK=
SN12C Mn:5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVPJR|UxRTNwMkS3NFEh|ryP MoO5V2FPT0WU
786-0 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWXPW4xDUUN3ME2zMlI4OjR|IN88US=> MVLTRW5ITVJ?
GAK MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{jDSGlEPTB;Mz6zNlU3OSEQvF2= M4fyXXNCVkeHUh?=
PANC-03-27 NYXHUld{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M17YWGlEPTB;Mz6zOVA1PSEQvF2= M{L0UHNCVkeHUh?=
CTB-1 NHvJTW5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWj1[2c4UUN3ME2zMlQ4ODR5IN88US=> NY\oVI0{W0GQR1XS
A427 NILsSlhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWXJR|UxRTNwNUm1OVYh|ryP MYTTRW5ITVJ?
EGI-1 MoTlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXn0[3lrUUN3ME2zMlYxPTh|IN88US=> NE\GOGRUSU6JRWK=
U-2-OS M{TSc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVXJR|UxRTNwNkeyOVYh|ryP MoPZV2FPT0WU
NCI-SNU-5 M2DEfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWH4V2ZKUUN3ME2zMlY4PzNizszN MmnqV2FPT0WU
SK-LU-1 NEDqWoVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEXuOJdKSzVyPUOuOlg4QThizszN M1\mc3NCVkeHUh?=
697 M3XLRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYLJR|UxRTNwNkm2NFMh|ryP NUfmdZc6W0GQR1XS
HPAF-II NETkepVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3vpbmlEPTB;Mz63OVQ6KM7:TR?= M3;GNnNCVkeHUh?=
NCI-H2087 NEDkeHVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV7JR|UxRTNwOES2O|Ih|ryP MX\TRW5ITVJ?
SK-MEL-3 NH3xfVlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MojaTWM2OD1|Lki1NVU1KM7:TR?= NUjqTlFlW0GQR1XS
CGTH-W-1 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIjR[FdKSzVyPUOuPFU4OjVizszN NXzNRVFnW0GQR1XS
8505C Mmm0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWnJR|UxRTNwOUCwO|gh|ryP MVnTRW5ITVJ?
GAMG M1W5R2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUG1N|dzUUN3ME20MlAzOzd5IN88US=> NEHEUoVUSU6JRWK=
SW626 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUDmVWRXUUN3ME20MlA1PDhizszN NXTWXnR1W0GQR1XS
CAL-62 Mk\vS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml7KTWM2OD12LkC3OFMh|ryP NXzr[YxOW0GQR1XS
MHH-PREB-1 NGjLfHZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFq2U5BKSzVyPUSuNVIyOTFizszN NIf3XXRUSU6JRWK=
RPMI-7951 NYnmSodlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MofFTWM2OD12LkK1OVg6KM7:TR?= MXTTRW5ITVJ?
HOP-92 NFzaNZRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3vOUmlEPTB;ND6yOVY4KM7:TR?= Mkj4V2FPT0WU
MDA-MB-231 M2mwZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVqzfGxVUUN3ME20MlI6OjJ|IN88US=> NFTzUXlUSU6JRWK=
LAN-6 Mkf1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWnFR2hNUUN3ME20MlMyPjN5IN88US=> MX3TRW5ITVJ?
ALL-PO MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NInFUWFKSzVyPUSuN|YyPTZizszN MmHqV2FPT0WU
HH MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlThTWM2OD12LkSxOVk4KM7:TR?= NUnuRYtwW0GQR1XS
IGROV-1 NVfSW21kT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnrZTWM2OD12LkS1NVcyKM7:TR?= NFW1OXBUSU6JRWK=
NCI-H358 M2XSNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MY\JR|UxRTRwNEWzPFUh|ryP MXXTRW5ITVJ?
NB5 NVr5bI1FT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1r2[mlEPTB;ND62NFM3QSEQvF2= MoXSV2FPT0WU
NCI-H747 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVLDWpl5UUN3ME20MlY5QDB5IN88US=> NHXNbIVUSU6JRWK=
NH-12 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M37IemlEPTB;ND63NVYzPSEQvF2= MmS1V2FPT0WU
LB1047-RCC NFz5NYtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVLJR|UxRTRwN{O4NVUh|ryP M{C0WHNCVkeHUh?=
EFO-27 M{XUT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{fmXmlEPTB;ND63PFY3PyEQvF2= MWHTRW5ITVJ?
EPLC-272H NGDhd4ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NG\KSI5KSzVyPUSuPVk3PjlizszN NHX3VnNUSU6JRWK=
CAL-54 MoLmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4HScWlEPTB;NT6wNlY6PSEQvF2= NVTLWI9HW0GQR1XS
H4 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIjV[FlKSzVyPUWuNFQzPTVizszN NHrkd2RUSU6JRWK=
MOLT-13 NF[5fHpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3fOdGlEPTB;NT6wOlc4PiEQvF2= MnLwV2FPT0WU
CAL-33 NXnifpNZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmHmTWM2OD13LkGyN|E4KM7:TR?= M4LReHNCVkeHUh?=
23132-87 NH30OoxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYLJR|UxRTVwMU[4O|Ih|ryP MnuwV2FPT0WU
UM-UC-3 NWK0cWtCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVfJR|UxRTVwMUiwOFch|ryP NH3BSWpUSU6JRWK=
HuH-7 NVnQVpZ4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYLhTXhJUUN3ME21MlI4OTR5IN88US=> NI\YellUSU6JRWK=
BCPAP NEL2dppIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH7aXoJKSzVyPUWuN|I6PjlizszN MWTTRW5ITVJ?
AsPC-1 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXriNIt3UUN3ME21MlM3PzZ|IN88US=> MUDTRW5ITVJ?
NCI-H1155 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4rtb2lEPTB;NT60NFA2OSEQvF2= NFm5[FlUSU6JRWK=
GT3TKB MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MW\JR|UxRTVwNE[1PVgh|ryP MV;TRW5ITVJ?
HCC2998 MknMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWCweo56UUN3ME21MlQ6OTB7IN88US=> NXzNenFrW0GQR1XS
NUGC-3 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYDwbY1ZUUN3ME21MlQ6OzB{IN88US=> NVi2UoMzW0GQR1XS
Hs-578-T MmPoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MonwTWM2OD13LkWzO|k1KM7:TR?= MoniV2FPT0WU
FADU M2Tmb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkXiTWM2OD13LkW1O|I3KM7:TR?= Mk\sV2FPT0WU
NBsusSR M160[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFTaUFhKSzVyPUWuOVcyPTVizszN M2TCcHNCVkeHUh?=
ME-180 M4\kb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1OzPWlEPTB;NT61PFA6OiEQvF2= M1nRTHNCVkeHUh?=
SW1710 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVzJR|UxRTVwNkG2OVQh|ryP NUDEfYpjW0GQR1XS
HuP-T3 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYDFc2FzUUN3ME21MlYzODJ7IN88US=> NYi0NHRqW0GQR1XS
HOS NVXYdpBFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXPJR|UxRTVwNkK5NlMh|ryP MXnTRW5ITVJ?
PA-1 NVXr[21KT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF\oVIFKSzVyPUWuOlQzPjVizszN NWPIOHpmW0GQR1XS
LU-99A M4jpb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX[0eJlFUUN3ME21MlY3PDVzIN88US=> NXLFcWUxW0GQR1XS
RS4-11 NVnhNYZyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF;0fI5KSzVyPUWuOlY4PzVizszN M2LEPXNCVkeHUh?=
TE-8 MliwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1jWb2lEPTB;NT62PFU{PyEQvF2= MlLYV2FPT0WU
RERF-LC-MS NYH5VlBrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGjiWHBKSzVyPUWuOlg5ODNizszN NILteINUSU6JRWK=
MEL-JUSO Mmr2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mo\qTWM2OD13LkezO|gh|ryP NInvXJpUSU6JRWK=
SK-MES-1 NWDsXIdwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkXPTWM2OD13LkizOVI5KM7:TR?= M1fmOnNCVkeHUh?=
D-263MG NVzSTHo1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mnv6TWM2OD13Lki4N|UyKM7:TR?= MlnZV2FPT0WU
NB10 NV3zS4tIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV3JR|UxRTVwOEm0OkDPxE1? Mon3V2FPT0WU
SK-HEP-1 M4jOVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoPqTWM2OD13LkmzOFcyKM7:TR?= NGHkOVVUSU6JRWK=
HT-29 NIfifZBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWHl[GRFUUN3ME21Mlk5OTF6IN88US=> NF;JVVVUSU6JRWK=
KYSE-140 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2H2b2lEPTB;Nj6wNlE5OiEQvF2= MYTTRW5ITVJ?
NCI-H1666 M2\QUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWSzXoY4UUN3ME22MlA5PDZzIN88US=> MUfTRW5ITVJ?
NCI-H1304 NYDkUm86T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1jqVmlEPTB;Nj6xPVk1KM7:TR?= MmPIV2FPT0WU
RPMI-8866 NFfnVJVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4fYOGlEPTB;Nj6yNVMyOyEQvF2= NW\ScZg6W0GQR1XS
MV-4-11 MoPQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX\EZoU6UUN3ME22MlI{OTl7IN88US=> M1rDfnNCVkeHUh?=
A431 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1e5TmlEPTB;Nj6yOFI6PiEQvF2= NHHNUXNUSU6JRWK=
PANC-10-05 NHzWRYFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml;aTWM2OD14LkK4N|Y{KM7:TR?= NGr6fWFUSU6JRWK=
TK10 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYnUXnVRUUN3ME22MlMzPjB2IN88US=> NU\obGV4W0GQR1XS
NCI-H1975 NHfQSGNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4XsVWlEPTB;Nj60O|IyPSEQvF2= NEnhRoxUSU6JRWK=
A172 NFfpbmZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXjHO5k{UUN3ME22MlQ6OTd4IN88US=> NWe1NopTW0GQR1XS
D-566MG Mn7DS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkDPTWM2OD14LkW0N|A{KM7:TR?= NVvvUIl3W0GQR1XS
NCI-H2122 NHnrdIdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4LLS2lEPTB;Nj62NVUzQCEQvF2= NYnVfFdGW0GQR1XS
COR-L105 NXTWNpR5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnPXTWM2OD14Lk[1Nlc2KM7:TR?= M3\I[3NCVkeHUh?=
AN3-CA NVLFSVBKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVT5O4RpUUN3ME22MlY5PjRzIN88US=> NILZPJdUSU6JRWK=
Calu-6 M1PpNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmO3TWM2OD14Lke5Olk5KM7:TR?= MYjTRW5ITVJ?
HCT-116 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2Xl[GlEPTB;Nj64NVI3PCEQvF2= NUjnSoRxW0GQR1XS
MHH-NB-11 M3TJTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoHRTWM2OD14Lki1NFAzKM7:TR?= NXzOPXhOW0GQR1XS
MFE-280 M3vPWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnnxTWM2OD14Lki1PVg{KM7:TR?= NIPJTG1USU6JRWK=
SW1088 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFP0VZdKSzVyPU[uPVE6OTNizszN NXTkeWt4W0GQR1XS
SW48 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHrUOm5KSzVyPU[uPVQ2OSEQvF2= MmLJV2FPT0WU
HuCCT1 M3z6bGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGDRUJVKSzVyPUeuNFExOzdizszN MmfmV2FPT0WU
ACHN NILvVFJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYrJR|UxRTdwMEK5OFMh|ryP NW\kd3F[W0GQR1XS
8305C M1XVXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4TVemlEPTB;Nz6wPVk6PSEQvF2= MXTTRW5ITVJ?
DoTc2-4510 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmSzTWM2OD15LkGyNVUh|ryP NUfxTnF[W0GQR1XS
COR-L23 MmDMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWDnOnE6UUN3ME23MlI1PDJizszN NIfmbJVUSU6JRWK=
SK-MEL-30 NVH5SGNWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml\JTWM2OD15LkK1NFg{KM7:TR?= M2e2N3NCVkeHUh?=
BE-13 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVHuRoFTUUN3ME23MlM{QDN2IN88US=> M2DMbXNCVkeHUh?=
GR-ST M{jN[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlrvTWM2OD15LkSwNVc1KM7:TR?= MknjV2FPT0WU
LU-135 M1fsO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3HjXmlEPTB;Nz61OVk{QSEQvF2= NVr3RXFwW0GQR1XS
U-266 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1\iUGlEPTB;Nz61OlI5PiEQvF2= MoDQV2FPT0WU
NCI-H1355 MknRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYPlbY1mUUN3ME23MlU5PjN3IN88US=> NGO4d3ZUSU6JRWK=
NB14 NXz3PZc{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2PpbWlEPTB;Nz62OlY1OiEQvF2= NFPVWoxUSU6JRWK=
SCC-25 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYq0PItVUUN3ME23MlcxQSEQvF2= NFfzd4ZUSU6JRWK=
COLO-678 M{LuTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mof0TWM2OD15LkexNFc3KM7:TR?= NX\HTnhNW0GQR1XS
TGBC1TKB MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX3JR|UxRTdwOEmzPVgh|ryP MXnTRW5ITVJ?
IST-MEL1 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGKwcVdKSzVyPUiuNFA1ODZizszN MV7TRW5ITVJ?
ECC10 NHTrWVBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXrqPVdlUUN3ME24MlA{Ozl3IN88US=> NWnl[ZN6W0GQR1XS
EW-16 NFT4U|ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnKxTWM2OD16LkC4OFQ2KM7:TR?= MmHKV2FPT0WU
DOHH-2 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3TPfmlEPTB;OD6yNFA6PSEQvF2= MYDTRW5ITVJ?
NCI-H1581 NGjJcJJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVjRcG5pUUN3ME24MlI3OzJ|IN88US=> Ml3WV2FPT0WU
TE-5 M17SN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlXNTWM2OD16LkSyOFI6KM7:TR?= MWLTRW5ITVJ?
CAKI-1 Mlu3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NU[wZoVXUUN3ME24MlU4OjJ{IN88US=> M2PkbHNCVkeHUh?=
A673 NYPHXYN2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFn6ZW5KSzVyPUiuOlMzODJizszN MkHXV2FPT0WU
CAL-12T MkL6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3XvTWlEPTB;OD62OVc2OyEQvF2= Ml\ZV2FPT0WU
DBTRG-05MG M{PReGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1rBV2lEPTB;OD63OFg2QSEQvF2= M3jVO3NCVkeHUh?=
SK-N-FI M4fFZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnTITWM2OD16LkixN|c6KM7:TR?= NGf2cXRUSU6JRWK=
K-562 NUG5[IR[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mo[3TWM2OD16LkizPVU4KM7:TR?= M1OyO3NCVkeHUh?=
SBC-1 Mm\nS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{PHTWlEPTB;OD64OlY1PSEQvF2= Mm\kV2FPT0WU
ES4 MmfqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXTJR|UxRThwOE[4PFQh|ryP MWTTRW5ITVJ?
MS-1 Mlz5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4[3e2lEPTB;OD64O|UyPyEQvF2= NV\lfoJzW0GQR1XS
RKO MlnOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXPJR|UxRThwOEmwOVch|ryP MUHTRW5ITVJ?
NCI-H1693 M1jSdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGL4eohKSzVyPUiuPVIyPyEQvF2= MlLqV2FPT0WU
SW954 NFPyUoRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4PqV2lEPTB;OD65Olk4QCEQvF2= M37iTHNCVkeHUh?=
SK-UT-1 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFOyb4tKSzVyPUiuPVc3QDNizszN M3jTeXNCVkeHUh?=
T98G MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2Pu[GlEPTB;OD65PVg1PiEQvF2= M13F[3NCVkeHUh?=
NCI-H2126 M1[2bWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWnJR|UxRTlwMEC4NlYh|ryP M2LHTHNCVkeHUh?=
TE-12 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmHQTWM2OD17LkCzN|Y4KM7:TR?= NVnGVnNjW0GQR1XS
DK-MG MkL0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1\EfGlEPTB;OT6yNVE6OSEQvF2= MUHTRW5ITVJ?
MEG-01 NFfGUppIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXjJR|UxRTlwMkS5N|Eh|ryP NETnS4lUSU6JRWK=
HCC1937 NWqyOHdDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYXN[|k6UUN3ME25MlI6ODlzIN88US=> M{mzWHNCVkeHUh?=
MKN45 Mk\CS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1f0d2lEPTB;OT60OVA3PSEQvF2= NXe0NnU3W0GQR1XS
NCI-H1792 NGK4S5VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVPXVZo4UUN3ME25MlQ2OjF7IN88US=> M{H3cHNCVkeHUh?=
SW1417 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIW3PWNKSzVyPUmuOVY5OzdizszN MnK4V2FPT0WU
639-V NHqyd4ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2ToRmlEPTB;OT62OFM5QCEQvF2= M3;rR3NCVkeHUh?=
P30-OHK MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4TTRWlEPTB;OT62OVMyPiEQvF2= MlHOV2FPT0WU
YKG-1 M4DoSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml\DTWM2OD17Lke1NFM{KM7:TR?= MXXTRW5ITVJ?
KGN NHLDNnFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWTJR|UxRTlwOEO3PVUh|ryP Mkm2V2FPT0WU
MSTO-211H NUP5TXpIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1nKXGlEPTB;OT65OVUzQSEQvF2= MWDTRW5ITVJ?
NCI-H1573 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUjJR|UxRTFyLkG1O|Qh|ryP MkjuV2FPT0WU
NCI-H720 Ml63S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH3MS2NKSzVyPUGwMlE6QDlizszN MlHKV2FPT0WU
KARPAS-45 Mkn4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3PU[mlEPTB;MUCuNlc6PSEQvF2= MUDTRW5ITVJ?
MDA-MB-175-VII MmfWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mmf5TWM2OD1zMD60PEDPxE1? MUPTRW5ITVJ?
SK-NEP-1 MlrDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVHKbXJHUUN3ME2xNE41QThzIN88US=> NI[0bWtUSU6JRWK=
MKN28 NUW0OXBwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4TK[mlEPTB;MUCuOVE5KM7:TR?= MYjTRW5ITVJ?
KYSE-520 NGCzepFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mm\jTWM2OD1zMD61NkDPxE1? MWrTRW5ITVJ?
KE-37 NFj4XoxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHL1[|lKSzVyPUGwMlUzPzJizszN MWHTRW5ITVJ?
VA-ES-BJ M1HQWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MY\JR|UxRTFyLkW2O{DPxE1? NYPqeo9HW0GQR1XS
CCRF-CEM M1ftU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mo[3TWM2OD1zMD61Olg1KM7:TR?= NYHU[|A3W0GQR1XS
GMS-10 M2faWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2O4XWlEPTB;MUCuOlA6PCEQvF2= MX3TRW5ITVJ?
NCI-H1623 Mlm1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVLJR|UxRTFyLk[zO|kh|ryP MVvTRW5ITVJ?
NEC8 NY\aeHM1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NW\JclNXUUN3ME2xNE44Pzd|IN88US=> NVP1[lRVW0GQR1XS
MOLT-16 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWjJR|UxRTFyLkixNVMh|ryP MnrPV2FPT0WU
DJM-1 M3\vTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHvPelNKSzVyPUGxMlA{PzlizszN Mn7RV2FPT0WU
U251 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoTKTWM2OD1zMT6wOFIh|ryP MornV2FPT0WU
SBC-5 NIjmTlRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUnSU5Y2UUN3ME2xNU4yPDZ5IN88US=> NWfKWpA2W0GQR1XS
SW756 NUjYbJFnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnThTWM2OD1zMT6yNVU1KM7:TR?= M{XyeHNCVkeHUh?=
KS-1 NGfPfIFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHPxRVNKSzVyPUGxMlI3OTlizszN MVvTRW5ITVJ?
SF295 MnPoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV\JR|UxRTFzLkOxNFQh|ryP NUC2eZozW0GQR1XS
YH-13 NEnGboJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHP6[VRKSzVyPUGxMlMzPjdizszN M{DwR3NCVkeHUh?=
SW837 NELEPGpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{DieWlEPTB;MUGuN|UxPiEQvF2= NHfu[VdUSU6JRWK=
KYSE-450 Mo\2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoK3TWM2OD1zMT60NFU4KM7:TR?= MnzuV2FPT0WU
KYSE-180 Ml;ZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnfhTWM2OD1zMT60PFIh|ryP NV;rSmZTW0GQR1XS
S-117 NUHZV5E1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYn0XpBVUUN3ME2xNU41QDl4IN88US=> NH;3NVhUSU6JRWK=
KOSC-2 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYDqe4FiUUN3ME2xNU43OjJ{IN88US=> M1jUVHNCVkeHUh?=
KYSE-270 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF7M[3NKSzVyPUGxMlg4PDVizszN NX72S2E5W0GQR1XS
D-336MG MkLGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUHJR|UxRTFzLkmwO|Uh|ryP NUDHN4pFW0GQR1XS
KALS-1 NITUR4dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX\MWJN7UUN3ME2xNk4xODF4IN88US=> NWfSUYpPW0GQR1XS
LB373-MEL-D NET5WmJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWjJR|UxRTF{LkC1N|Mh|ryP MVHTRW5ITVJ?
HLE NWHVeVZvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV\JR|UxRTF{LkC1PFUh|ryP MlHNV2FPT0WU
SJSA-1 NV7aUYZ[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3T1N2lEPTB;MUKuNFc{PSEQvF2= NIn6d|BUSU6JRWK=
SW1990 NFnjepRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWrJR|UxRTF{LkC5NVEh|ryP NFj1NlhUSU6JRWK=
NOS-1 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2rDb2lEPTB;MUKuNVM2OiEQvF2= MUnTRW5ITVJ?
GI-ME-N MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXXJfotPUUN3ME2xNk4zOTZ|IN88US=> NWj2NYxGW0GQR1XS
NCI-H1703 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4fGSWlEPTB;MUKuNlYyPiEQvF2= M{LXPXNCVkeHUh?=
ES7 Mk\xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M16xWGlEPTB;MUKuNlczPCEQvF2= NGC1XYVUSU6JRWK=
KYSE-510 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIPBOWRKSzVyPUGyMlUxPzlizszN MVLTRW5ITVJ?
BHY M37tTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3m5TmlEPTB;MUKuOVMxPyEQvF2= M3raSnNCVkeHUh?=
TCCSUP NYfRcJZpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYnX[Jp6UUN3ME2xNk42PzV5IN88US=> MkfoV2FPT0WU
HSC-2 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV;4[5Z3UUN3ME2xNk42QTl4IN88US=> M2fjTnNCVkeHUh?=
BEN MkTrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml73TWM2OD1zMj62NVQ{KM7:TR?= Mki2V2FPT0WU
769-P MmS3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3XxTmlEPTB;MUKuO|kzPCEQvF2= MW\TRW5ITVJ?
HT NEHvUYtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFHj[3BKSzVyPUGyMlg{PDZizszN NEjVS3dUSU6JRWK=
LXF-289 NX\oSlVDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVnJR|UxRTF{Lkm1N|Eh|ryP M2\ONXNCVkeHUh?=
OVCAR-3 NUfkfW5WT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXnHbFg{UUN3ME2xNk46PTZ5IN88US=> M33qNnNCVkeHUh?=
ATN-1 M32zeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mo\3TWM2OD1zMz6wNVg1KM7:TR?= MXLTRW5ITVJ?
8-MG-BA M1X0NWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn3NTWM2OD1zMz6wOFU2KM7:TR?= MVnTRW5ITVJ?
SW13 M{f0cGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1PTdWlEPTB;MUOuNVE3PSEQvF2= MULTRW5ITVJ?
NCI-H1092 NHP5UXJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4qyOmlEPTB;MUOuNVYzKM7:TR?= MXPTRW5ITVJ?
OAW-42 M4O1fGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{XXXGlEPTB;MUOuNVk{PyEQvF2= NGj2boRUSU6JRWK=
NCI-H2452 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUnIZo5EUUN3ME2xN{4zOTd3IN88US=> MX3TRW5ITVJ?
CAPAN-1 MmflS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2T1dGlEPTB;MUOuOVUyPCEQvF2= NIHwcnRUSU6JRWK=
NCI-H2009 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkXHTWM2OD1zMz61PVE6KM7:TR?= MYTTRW5ITVJ?
SF268 NXT2OpJKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2jhb2lEPTB;MUOuOlMzPiEQvF2= NEP1W4VUSU6JRWK=
GCIY NV7TbZdWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGS3cmJKSzVyPUGzMlY6OjdizszN MU\TRW5ITVJ?
OS-RC-2 M4nOU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVLJR|UxRTF|Lkm1NFEh|ryP MoT1V2FPT0WU
GCT M{jlRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NG\FZ5JKSzVyPUGzMlk3QTdizszN NYqwZnpMW0GQR1XS
NB17 M4DiOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXzjZWx6UUN3ME2xOE4xQDVizszN MXrTRW5ITVJ?
NCI-H2030 NYPlWYNjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4[zVmlEPTB;MUSuNVQ3PSEQvF2= NUnpOlJFW0GQR1XS
HC-1 MmrDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1LzTWlEPTB;MUSuNlA5PyEQvF2= M{\PW3NCVkeHUh?=
QIMR-WIL NVXZclE1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGLWNVhKSzVyPUG0MlM1OTJizszN NXP1T5l1W0GQR1XS
Capan-2 M{TJS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmTNTWM2OD1zND6zO|E1KM7:TR?= NGnGS4xUSU6JRWK=
BALL-1 MmHDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NI[1RWFKSzVyPUG0MlQ3PjVizszN MWnTRW5ITVJ?
LS-1034 M2rHcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF3kZndKSzVyPUG0MlYyPTJizszN NELjXZdUSU6JRWK=
U-118-MG MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1nDcGlEPTB;MUSuOlMyKM7:TR?= NEC2S5RUSU6JRWK=
NCI-H630 M{[3e2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFW4WpNKSzVyPUG0MlY2PjhizszN NXzkZnE6W0GQR1XS
OVCAR-8 MlXES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGmwXZRKSzVyPUG0MlczODFizszN M{DmbnNCVkeHUh?=
NCI-H2347 NVi0NFJST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEXnUHdKSzVyPUG0MlgzOyEQvF2= M2H2NnNCVkeHUh?=
BT-549 M2KyUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmDLTWM2OD1zND64Nlg1KM7:TR?= NVzVU4tRW0GQR1XS
LB831-BLC M{TaPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MonjTWM2OD1zND64PVM1KM7:TR?= MoLvV2FPT0WU
NCI-H661 M3v0emdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVHZWYtnUUN3ME2xOE46PTlizszN M3vhVHNCVkeHUh?=
MKN7 MlO1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3zIeGlEPTB;MUWuNFA6OyEQvF2= MlXaV2FPT0WU
U-87-MG M3HFbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUPJR|UxRTF3LkC4PVch|ryP NYHVbmlPW0GQR1XS
OVCAR-4 NYfSUGdmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mm\KTWM2OD1zNT6xOFI1KM7:TR?= NXHo[5RCW0GQR1XS
OE33 MlzKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1X4SWlEPTB;MUWuNVcyOSEQvF2= M2WyVHNCVkeHUh?=
EC-GI-10 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUHO[nI2UUN3ME2xOU4zOzV5IN88US=> M2m5T3NCVkeHUh?=
AM-38 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWm1[ZpuUUN3ME2xOU4zPzF5IN88US=> NYHvWoZuW0GQR1XS
NCI-H1563 M4GxUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{Tse2lEPTB;MUWuN|Q6KM7:TR?= Ml\JV2FPT0WU
SCC-4 MnvFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVfOSFNFUUN3ME2xOU41OTB|IN88US=> NGPSUmpUSU6JRWK=
Detroit562 MlzrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXzJR|UxRTF3LkS1OFch|ryP NX;RfYRoW0GQR1XS
PC-14 MoS3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mk[zTWM2OD1zNT60PFY3KM7:TR?= M4PwNXNCVkeHUh?=
ES3 NX;4OGV6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmW2TWM2OD1zNT61N|Yh|ryP Mof3V2FPT0WU
OCI-AML2 NHHMdmlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGKwWoFKSzVyPUG1Mlc3OTRizszN NWP5T25VW0GQR1XS
LU-134-A MnPUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml3mTWM2OD1zNT65NFE5KM7:TR?= NVfKVlJkW0GQR1XS
SAS NWXpPZJmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MorUTWM2OD1zNT65N|c{KM7:TR?= NGf0eoNUSU6JRWK=
TGBC11TKB NGG3T2FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYDJR|UxRTF3Lkm0NVQh|ryP NGnMfYhUSU6JRWK=
HOP-62 NUDYcXppT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmnwTWM2OD1zNT65OVk4KM7:TR?= Mn;mV2FPT0WU
G-401 NFTjb3JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGfaNHRKSzVyPUG1Mlk3PDlizszN M2DrenNCVkeHUh?=
NCI-H28 M3XBTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWXLdZROUUN3ME2xOk4xQDV4IN88US=> NXfWfpFyW0GQR1XS
A204 MonFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1jQdGlEPTB;MU[uNlAxPiEQvF2= MlTEV2FPT0WU
NCI-H1299 M1LueWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFfwT2dKSzVyPUG2MlIzQTFizszN NIXyXHZUSU6JRWK=
VMRC-RCZ NFrySFVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3v3WmlEPTB;MU[uNlU6OiEQvF2= MnGwV2FPT0WU
BxPC-3 NWT1VVZqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmrNTWM2OD1zNj6yPFU3KM7:TR?= MWjTRW5ITVJ?
NCI-H2228 NEjSbW9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUHJR|UxRTF4LkWxOVgh|ryP NETQRVNUSU6JRWK=
NCI-H23 MkLvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFHTPYVKSzVyPUG2MlYxPzhizszN MXrTRW5ITVJ?
NKM-1 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWnBfFhFUUN3ME2xO{4xOTh7IN88US=> MWPTRW5ITVJ?
KYSE-70 MljZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml;JTWM2OD1zNz6yPFkh|ryP M1zR[HNCVkeHUh?=
BB49-HNC NHOwe4FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEfve4JKSzVyPUG3MlU3QDZizszN MmHFV2FPT0WU
SCC-15 NYn5T2xUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{L2VWlEPTB;MUeuPFQ4OyEQvF2= MV7TRW5ITVJ?
D-247MG M2LoNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV;JR|UxRTF5LkmyOFch|ryP NHHWSWlUSU6JRWK=
BB30-HNC NUn5PY9ST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVz0VoFsUUN3ME2xPE4xOzF6IN88US=> MoXHV2FPT0WU
CAL-85-1 NEfCRmhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWLlUpJSUUN3ME2xPE4yQDB7IN88US=> M{\1OHNCVkeHUh?=
HT-3 M1G5W2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnLVTWM2OD1zOD6zPVc4KM7:TR?= NI\XSpFUSU6JRWK=
KYSE-410 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoGyTWM2OD1zOD60OVc4KM7:TR?= MojNV2FPT0WU
SW982 MlHES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3PqS2lEPTB;MUiuOVY1QSEQvF2= M2HrPXNCVkeHUh?=
SW962 NFHOV4pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYfJR|UxRTF6LkW3NFIh|ryP MkD4V2FPT0WU
Ramos-2G6-4C10 NHPoXFNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M33tVGlEPTB;MUiuOVkzPyEQvF2= MUHTRW5ITVJ?
OC-314 NIL0d3pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn:5TWM2OD1zOD63N|g1KM7:TR?= MnjmV2FPT0WU
LS-123 NIXxe41Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFLWXlJKSzVyPUG4Mlc6ODFizszN MVLTRW5ITVJ?
D-502MG NYLhVnhWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX;JR|UxRTF6LkixN|kh|ryP M2O3R3NCVkeHUh?=
RO82-W-1 NYnmXoFFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHXjWGNKSzVyPUG4MlgzQDhizszN MlHkV2FPT0WU
HuO9 MonYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlHKTWM2OD1zOT6xN|c6KM7:TR?= NYfBRlRqW0GQR1XS
ETK-1 MmrLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXnseGZDUUN3ME2xPU4yQDJ5IN88US=> MWTTRW5ITVJ?
SNU-387 NHvLcpJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3[3[mlEPTB;MUmuNVg5QSEQvF2= MUTTRW5ITVJ?
SW1573 M1;TTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYTRTIdPUUN3ME2xPU4yQTZ7IN88US=> M1zWdXNCVkeHUh?=
NTERA-S-cl-D1 NXjlS|RbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWrxfVNzUUN3ME2xPU4zODB5IN88US=> MoT6V2FPT0WU
SF126 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYr0SXQ1UUN3ME2xPU4{PTB{IN88US=> NVPMUo45W0GQR1XS
Calu-3 NW\Pc2FUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4PZT2lEPTB;MUmuOFI{PyEQvF2= M4TUNnNCVkeHUh?=
NCI-H1048 MnnTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3HXO2lEPTB;MkCuN|I3PiEQvF2= NFXLUZlUSU6JRWK=
NCI-H226 NFfzOHVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2Hq[2lEPTB;MkCuOFM6QSEQvF2= NWfFOZBYW0GQR1XS
FTC-133 M3jqWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoHkTWM2OD1{MD60O|A{KM7:TR?= MoPDV2FPT0WU
SF539 NH3nfXlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX\JR|UxRTJyLkWxO|Ih|ryP MmfDV2FPT0WU
TE-6 NYTs[YhVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUTQOoI4UUN3ME2yNE45ODZ5IN88US=> MV7TRW5ITVJ?
UMC-11 M4TPWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NG\IRXBKSzVyPUKwMlkyPjRizszN NUnJWIpxW0GQR1XS
Becker Mli1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUHJR|UxRTJzLkGxNVgh|ryP M{TZSXNCVkeHUh?=
KP-4 NHLvdZNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEi1fm5KSzVyPUKxMlEyQTZizszN MVLTRW5ITVJ?
ChaGo-K-1 M2XLWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFLaPIxKSzVyPUKxMlM3OjdizszN MXrTRW5ITVJ?
CFPAC-1 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH\PbYVKSzVyPUKxMlM5PThizszN NH7rPG1USU6JRWK=
A498 M{nHSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV\JR|UxRTJzLkWzNVIh|ryP NWnXWXB[W0GQR1XS
NCI-H1755 NX7SPJhPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2XLbmlEPTB;MkGuOlc1OSEQvF2= MmmzV2FPT0WU
TI-73 NYG5bVU3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MULJR|UxRTJ{LkOyPEDPxE1? M2TxcHNCVkeHUh?=
NCI-H441 M3zMR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXLK[2Z2UUN3ME2yNk42Pjh7IN88US=> NYL5N|Q5W0GQR1XS
CaR-1 M{\vRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1rQd2lEPTB;MkOuNFIyOyEQvF2= NX:3NWJyW0GQR1XS
HCC1806 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV;JR|UxRTJ|LkC1PFMh|ryP MoLTV2FPT0WU
SNU-449 M1;MbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mof1TWM2OD1{Mz6zNlkh|ryP MoD5V2FPT0WU
EKVX M3y3Rmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH74[|dKSzVyPUKzMlM6ODlizszN Ml;NV2FPT0WU
DMS-114 MoWxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn\2TWM2OD1{Mz61O|Y2KM7:TR?= M2HRUnNCVkeHUh?=
A704 NYT5e4NGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUHBS5ZzUUN3ME2yN{43OTB|IN88US=> NGTGdHNUSU6JRWK=
LC-2-ad MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH;rfYVKSzVyPUKzMlYyPDdizszN MUPTRW5ITVJ?
VM-CUB-1 NIfqZWxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEPneVdKSzVyPUKzMlc{PDFizszN MYrTRW5ITVJ?
PC-3 NUHYcphDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIXF[I9KSzVyPUK0MlA2OjZizszN MkTNV2FPT0WU
HEL NXnC[WxjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYLJ[4JJUUN3ME2yOE4xQDZ3IN88US=> M4PXcHNCVkeHUh?=
ABC-1 NGLOV4tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmO5TWM2OD1{ND6yO|I6KM7:TR?= MnPYV2FPT0WU
COLO-680N NF\KOHBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUjqW|huUUN3ME2yOE41PzZ2IN88US=> MXLTRW5ITVJ?
MZ1-PC Mln1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NG\IZ5VKSzVyPUK0MlY5PyEQvF2= NUj0XpNrW0GQR1XS
NCI-H69 NX3zcmh{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXLSeGRNUUN3ME2yOE44OzV2IN88US=> NXjyOZJ{W0GQR1XS
TE-1 MlzBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnzwTWM2OD1{NT6wOFk6KM7:TR?= MmrYV2FPT0WU
EW-3 NInxVIFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHrp[I9KSzVyPUK1MlEyOyEQvF2= NEfQcFBUSU6JRWK=
PANC-08-13 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mk\OTWM2OD1{NT64NVA{KM7:TR?= M1:3NnNCVkeHUh?=
NMC-G1 NGPNO3JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX3JR|UxRTJ4LkCwPFgh|ryP NXjYd4IzW0GQR1XS
BT-20 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmHwTWM2OD1{Nj60OVQ{KM7:TR?= NITZeWNUSU6JRWK=
TGBC24TKB MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2DxVWlEPTB;Mk[uO|M{OSEQvF2= Ml7yV2FPT0WU
TE-11 M1HISWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVXJR|UxRTJ4Lkm4PVUh|ryP MnnvV2FPT0WU
ESS-1 NWH2S2h6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX7CWYxZUUN3ME2yO{4{OjF4IN88US=> MlnWV2FPT0WU
JVM-3 M2TGOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3nISGlEPTB;MkeuOlQ4PSEQvF2= NFjYVG5USU6JRWK=
C3A M4\lbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX7pdJV1UUN3ME2yO{45PDl4IN88US=> MoXKV2FPT0WU
MDA-MB-157 MmKxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFTaVldKSzVyPUK3Mlg4PTNizszN NWezSXloW0GQR1XS
KLE M3rKdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYLVWXhvUUN3ME2yPE4yODV6IN88US=> NHXsVGNUSU6JRWK=
ES1 NVS5WYNZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3Tq[2lEPTB;MkiuNVg{QCEQvF2= MoTaV2FPT0WU
CAL-120 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUK0TZY1UUN3ME2yPE4{QTl7IN88US=> NUnrSm1PW0GQR1XS
NCI-N87 MoXKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV3CUJZlUUN3ME2yPE42OTB3IN88US=> MmnaV2FPT0WU
RPMI-8226 M{K2S2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NI\EeHBKSzVyPUK5MlE5PDNizszN M{CwcXNCVkeHUh?=
COR-L88 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnXRTWM2OD1{OT6yOFE6KM7:TR?= NYq5T4pGW0GQR1XS
UACC-893 Mke4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWDoWFc4UUN3ME2yPU4{OTN5IN88US=> MV7TRW5ITVJ?
C8166 M2\Xdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkHTTWM2OD1{OT65PVk3KM7:TR?= MnXTV2FPT0WU
J82 M{HnSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYnJR|UxRTNyLkixOFch|ryP MYLTRW5ITVJ?
PFSK-1 NVnLfGtjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX3JR|UxRTNzLkC2OVkh|ryP NWPqbVc6W0GQR1XS
COLO-684 NIXZc5dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NITEXWFKSzVyPUOxMlQ{PzRizszN NF7lO|dUSU6JRWK=
CAL-72 NI\ieVlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MojsTWM2OD1|MT61O|I6KM7:TR?= M2f3eXNCVkeHUh?=
SNB75 M{LLfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH;1VnFKSzVyPUOxMlg6PyEQvF2= MWrTRW5ITVJ?
MDA-MB-415 NXz6XXhjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1fqeGlEPTB;M{GuPVc3OiEQvF2= NYDmPHk4W0GQR1XS
SiHa MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFqwcXdKSzVyPUOyMlQ4OTFizszN MnjDV2FPT0WU
NCI-H1648 NUDGeHd5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{Ts[mlEPTB;M{KuPVM1PSEQvF2= MnfzV2FPT0WU
EFO-21 NH\QV4pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWi4eXlYUUN3ME2zN{4xODVizszN NV[xTppIW0GQR1XS
HCC38 NHTQSXNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXLJR|UxRTN|LkO4OFEh|ryP MlzrV2FPT0WU
IA-LM MmPyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF7OTJZKSzVyPUOzMlc5QDlizszN NV[wVWlrW0GQR1XS
CTV-1 NGjjbYZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWDJR|UxRTN|Lkm3PFYh|ryP MWPTRW5ITVJ?
NCI-H446 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUjFNZE3UUN3ME2zOE4zPjh7IN88US=> NX[0dIdqW0GQR1XS
IST-SL1 NFvyRZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoDITWM2OD1|ND63OFA5KM7:TR?= MmT5V2FPT0WU
EW-22 MkmwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYHWNIFIUUN3ME2zOE44PzV7IN88US=> M{TLOHNCVkeHUh?=
JEG-3 M2rEWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mlv1TWM2OD1|Nj6xO|Y3KM7:TR?= NETWVFRUSU6JRWK=
LU-65 NV62Zok4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4DmPGlEPTB;M{[uNlk5PSEQvF2= NIfudZlUSU6JRWK=
NCI-H596 NVLhe|JXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXjiVIRPUUN3ME2zOk46PTlzIN88US=> MlruV2FPT0WU
KNS-81-FD Mo\1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NInVUmlKSzVyPUO3MlE1PSEQvF2= NGDTPHhUSU6JRWK=
NCI-H1793 NGmyVG5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXLJR|UxRTN5LkewPFYh|ryP MYTTRW5ITVJ?
NCI-H460 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX;HSIV1UUN3ME2zPE4xQDd|IN88US=> MWLTRW5ITVJ?
MPP-89 NXO1bpp[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1TST2lEPTB;M{muOVg5PiEQvF2= M1HSOnNCVkeHUh?=
D-542MG NUfIZ4NFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYfJR|UxRTN7Lki0N|Yh|ryP NFP0SGpUSU6JRWK=
JAR MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXnJR|UxRTRyLkS3NFUh|ryP NFG0NnlUSU6JRWK=
NCI-H209 M1jXNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGDJ[5NKSzVyPUSwMlY4PyEQvF2= MnriV2FPT0WU
G-402 NF;ZeZdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUDvb2UxUUN3ME20NU4{QTl|IN88US=> M2qwT3NCVkeHUh?=
IST-MES1 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVrJR|UxRTR{LkG5N|Uh|ryP MX7TRW5ITVJ?
Daoy NEDJSHRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmPxTWM2OD12Mj61OFcyKM7:TR?= M3jsS3NCVkeHUh?=
EW-11 M3P0bGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVXJR|UxRTR|LkGyNVEh|ryP MnvQV2FPT0WU
Saos-2 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2XIdmlEPTB;NEOuNVU{PyEQvF2= M4[0bHNCVkeHUh?=
no-10 M{LSNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIjHNmRKSzVyPUSzMlE4ODJizszN MWnTRW5ITVJ?
HCC1395 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV\DS2N[UUN3ME20N{41PjR2IN88US=> MVzTRW5ITVJ?
HCE-4 M37O[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkniTWM2OD12Mz63OlY1KM7:TR?= M2rhUHNCVkeHUh?=
EW-1 M4m5TWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUnJR|UxRTR|LkiwOFkh|ryP MmTiV2FPT0WU
OCUB-M M3q5VGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVm3To9VUUN3ME20OE4{PjN6IN88US=> M4LDTnNCVkeHUh?=
IGR-1 NYrXUlZQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVj0SXRTUUN3ME20OE41OTF3IN88US=> NYjSW4tQW0GQR1XS
NCI-H1838 NH;Dem9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFzhV21KSzVyPUS0MlQ{PDlizszN M4PsO3NCVkeHUh?=
NCI-H2405 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFfGVJRKSzVyPUS0MlU{PCEQvF2= M1fpTHNCVkeHUh?=
GB-1 NXzZVHZrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml[yTWM2OD12ND63OFY{KM7:TR?= NEfQZ4pUSU6JRWK=
MG-63 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV:zTlNmUUN3ME20Ok4xPjl4IN88US=> M3\FdXNCVkeHUh?=
KP-N-YN NYrhe5hlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2HiO2lEPTB;NE[uOFY4QSEQvF2= MWnTRW5ITVJ?
no-11 NITJZXlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mmn5TWM2OD12Nz6wNlQ1KM7:TR?= MlTKV2FPT0WU
SW948 NIPjb2VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkjBTWM2OD12Nz6zN|c4KM7:TR?= NGrVVVBUSU6JRWK=
CAMA-1 M{jUOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MY\JR|UxRTR5LkO0N|gh|ryP M{LG[nNCVkeHUh?=
HCC1187 NX3mfpNxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFT5SFdKSzVyPUS3MlUyKM7:TR?= M{GzbHNCVkeHUh?=
D-392MG NGfIVm1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MojTTWM2OD12Nz62OVE3KM7:TR?= NF7zZm5USU6JRWK=
647-V MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmHXTWM2OD12OT6zOFE1KM7:TR?= M4DCUXNCVkeHUh?=

... Click to View More Cell Line Experimental Data

In vivo Oral dosing of CI-1040 impairs the growth of colon tumor xenografts of mouse and human with a wide dose range of 48-200 mg/kg per dose, but not of P388 leukemia. [1] CI-1040 inhibits the tumor xenografts from PTC cells carrying a BRAF mutation with 31.3% reduction, carrying the RET/PTC1 rearrangement with 47.5% reduction than in untreated (vehicle) mice after 3 weeks of oral administration (300 mg/kg/d). No toxic effects are observed in any mice when they are treated with CI-1040. [2] Transient exposure of mammary tumors to CI-1040 and UCN-01 causes tumor cell death in vivo and prolonged suppression of tumor regrowth. Combined treatment with CI-1040 (25 mg/kg) and UCN-01 (0.1-0.2 mg/kg) significantly reduces MDA-MB-231, and largely abolishs MCF7 tumor growth in implanted athymic mice, while either single treatment has no significant activity. The drug combination leads to profound tumor cell death which correlates with a reduction in the phosphorylation of ERK1/2 and the immuno-reactivity of Ki67 and of CD31. [5]

Protocol

Kinase Assay:

[2]

+ Expand

MEK1 Assay:

MAP kinase is activated after phosphorylation by MEK; the activated MAP kinase subsequently phosphorylates myelin basic protein (MBP).Incorporation of 32P into myelin basic protein (MBP) is assayed in the presence of glutathione S-transferase (GST) fusion proteins containing the 44-kDa MAPK (GST-MAPK) or the 45-kDa MEK (GST-MEK1). Assays are conducted in 50μL of 50 mM Tris, pH 7.4/10 mM MgCl2 /2 mM EGTA/10 μM [γ-32P]ATP containing 10 μg of GST-MEK1, 0.5 μg of GST-MAPK, and 40 μg of MBP. After incubation at 30°C for 15 minutes, reactions are stopped by addition of Laemmli SDS sample buffer. Phosphorylated MBP is resolved by SDS/10% PAGE. This screening effort leads to the discovery of several small-molecule inhibitors of MEK, i.e. CI-1040. Experiments assessing the order of addition shows that CI-1040 directly inhibits MEK1 with a 50% inhibitory concentration (IC50) of 17 nM, without affecting the activity of MAPK.
Cell Research:

[1]

+ Expand
  • Cell lines: Colon 26 carcinoma cells
  • Concentrations: 0.1-10 μM
  • Incubation Time: 24 hours
  • Method:

    Cells are planted seeded in T-75 cm 2 flasks and treated the next day for 24 hous with either DMSO or CI-1040. Single-cell suspensions are collected, and pellets are fixed in ice-cold ethanol (70%) for 30 minutes. After centrifugation of the samples, propidium iodide (50 μg/mL) and RNase (30 units/mL) are added to the pellets for 20 minutes at 37 °C. After filtration, samples are analyzed by flow cytometry.


    (Only for Reference)
Animal Research:

[3]

+ Expand
  • Animal Models: PTC cells in athymic mice
  • Formulation: Cremophor EL–95% ethanol (50:50) and dilutes with water
  • Dosages: 150 mg/kg
  • Administration: Orally twice daily
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 96 mg/mL (200.55 mM)
Ethanol 14 mg/mL (29.24 mM)
Water <1 mg/mL
In vivo 30% PEG400+0.5% Tween80+5% propylene glycol, pH 9 10 mg/mL

* 1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 478.67
Formula

C17H14ClF2IN2O2

CAS No. 212631-79-3
Storage powder
in solvent
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT00033384 Completed Breast Cancer|Colorectal Cancer|Lung Cancer|Pancreatic Cancer University of Alabama at Birmingham|National Cancer Institute (NCI) February 2002 Phase 2
NCT00034827 Completed Colorectal Neoplasms|Breast Neoplasms|Carcinoma, Non-Small-Cell Lung|Pancreatic Neoplasms Pfizer January 2002 Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

MEK Signaling Pathway Map

MEK Inhibitors with Unique Features

Related MEK Products

Tags: buy PD184352 (CI-1040) | PD184352 (CI-1040) supplier | purchase PD184352 (CI-1040) | PD184352 (CI-1040) cost | PD184352 (CI-1040) manufacturer | order PD184352 (CI-1040) | PD184352 (CI-1040) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID